Imunon, Inc. quarterly report, Q2 FY2014

Business context and reporting period

Celsion Corporation’s unaudited Form 10-Q covers the quarter and six months ended June 30, 2014. The filing identifies the registrant as Celsion Corporation, not Imunon, Inc. Celsion was a clinical-stage oncology drug developer; its lead candidate, ThermoDox, was in Phase III development, and it acquired substantially all assets of EGEN, Inc. on June 20, 2014.

Financial results and liquidity

Revenue was primarily the scheduled amortization of Hisun’s $5 million non-refundable technology-development payment; the company reported no meaningful product-sales revenue. Operating costs rose with OPTIMA trial preparation, ThermoDox manufacturing, higher personnel and stock compensation, and $1.07 million of EGEN acquisition costs. The 2013 comparison benefited from a substantial non-cash gain on warrant-liability revaluation; 2013 six-month loss attributable to common shareholders also included a $4.60 million non-cash deemed dividend.

At June 30, cash and cash equivalents were $9.60 million; available-for-sale investments were $40.17 million, with $0.29 million accrued interest. Celsion reported $50.1 million in cash, cash equivalents, investments and related interest, $42.7 million net working capital, and an accumulated deficit of $181.5 million. Management estimated available resources would fund operations into the second half of 2016, while warning that additional capital would be needed to develop and commercialize candidates.

Debt included $10 million principal under the Hercules facility, with a balance-sheet carrying amount of approximately $9.64 million after discounts. The loan bears a variable prime-based rate reported as 11.25% and is secured; up to a further $10 million was available under the facility. Total liabilities were $34.22 million, including a $13.88 million EGEN earnout liability. No profit margin is meaningful given minimal revenue and substantial operating losses.

Material changes versus the prior comparable period

• Second-quarter operating expenses increased 64.6% year over year; first-half expenses increased 33.8%. First-half R&D rose to $6.06 million from $5.23 million, while G&A rose to $4.74 million from $3.64 million.
• First-half operating cash use increased to $9.01 million from $3.40 million. Financing provided $18.78 million, principally from the January common-stock offering and the second $5 million Hercules draw.
• The June EGEN acquisition added $25.80 million of acquired in-process R&D and $1.94 million goodwill, based on preliminary purchase accounting. Celsion issued 2.71 million shares and paid approximately $3.0 million cash at closing; up to $30.4 million of further milestone payments may be due.
• Common shares issued increased to 20.08 million from 13.74 million at December 31, 2013. The January financing raised approximately $15 million gross and included warrants to purchase up to 1.80 million shares.

Outlook, management commentary, risks and unusual items

• ThermoDox’s earlier Phase III HEAT Study failed its primary progression-free-survival endpoint. Management reported a retrospective HEAT subgroup analysis suggesting a 57% overall-survival improvement for patients with single lesions treated by RFA for at least 45 minutes (HR 0.639; p=0.037); it cautioned that the subgroup analysis was retrospective and median survival had not been reached.
• The OPTIMA pivotal Phase III study was launched in the first half of 2014. It was designed to enroll approximately 550 patients, standardize RFA to at least 45 minutes, and use overall survival as its primary endpoint. FDA clearance followed its review period. The filing also describes plans for regulatory engagement in China and Europe.
• July 2014 interim DIGNITY results, disclosed after quarter-end, reported 10 evaluable patients: three complete responses, two partial responses and one stable disease; these early results are not established evidence of efficacy.
• Management expects continuing operating losses and no significant product revenue for the foreseeable future. The principal risks include clinical-trial failure or delay, regulatory and manufacturing hurdles, reliance on third parties, capital needs and dilution, and difficulty integrating EGEN. The acquisition’s purchase-price allocation was preliminary; acquired in-process R&D and goodwill are subject to impairment testing.
• Celsion reported no legal proceedings, no off-balance-sheet financing arrangements, and effective disclosure controls as of June 30, 2014. It stated that it complied with Hercules loan covenants.

Important facts for investors to verify

• Confirm the filing identity and period: this is Celsion Corporation’s 2014 second-quarter 10-Q, notwithstanding the Imunon metadata.
• Track OPTIMA enrollment, trial conduct and outcomes, and distinguish prospective trial evidence from retrospective HEAT subgroup findings.
• Assess the cash-burn trajectory against management’s stated runway and the capital required for clinical development; verify access to remaining Hercules financing and any further financing plans.
• Review EGEN milestone terms, potential cash or share settlement, integration progress, and changes to the preliminary $27.6 million acquisition valuation.
• Monitor dilution from outstanding warrants, options, reserved plan shares, EGEN holdback shares and potential earnout shares.